Epidermal growth factor inhibits Fas-mediated apoptosis in salivary epithelial cells of patients with primary Sjögren's syndrome

Clinical and Experimental Rheumatology

Volumn 25, Issue 6, 2007, Pages 831-837

  Nakamura, Hideki ^a   Kawakami, Atsushi ^a   Ida, Hiroaki ^a   Koji, Takehiko ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Akt; Apoptosis; Epidermal growth factor; NF B; Sj gren's syndrome

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; EPIDERMAL GROWTH FACTOR; FAS ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CASE REPORT; CELL CULTURE; CELL PROTECTION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; SALIVARY GLAND; SJOEGREN SYNDROME;

ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; CELLS, CULTURED; CHROMONES; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; FEMALE; HUMANS; IN SITU NICK-END LABELING; MORPHOLINES; NITRILES; SALIVARY GLANDS; SJOGREN'S SYNDROME; SULFONES;

EID: 38649117968     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. FOX RI: Sjögren's syndrome. Lancet 2005; 366: 321-31.
2. NAKAMURA H, KAWAKAMI A, EGUCHI K: Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren's syndrome. Transl Res 2006; 148: 281-8.
3. KONG L, OGAWA N, NAKABAYASHI T et al.: Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 1997; 40: 87-97.
4. MANGANELLI P, QUAINI F, ANDREOLI AM et al.: Quantitative analysis of apoptosis and bcl-2 in Sjögren's syndrome. J Rheumatol 1997; 24: 1552-7.
5. MATSUMURA R, UMEMIYA K, KAGAMI M et al.: Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjögren's syndrome. Clin Exp Rheumatol. 1998; 16: 561-8.
6. POLIHRONIS M, TAPINOS NI, THEOCHARIS SE, ECONOMOU A, KITTAS C, MOUTSOPOULOS HM: Modes of epithelial cell death and repair in Sjögren's syndrome (SS). Clin Exp Immunol 1998; 114: 485-90.
7. NAKAMURA H, KAWAKAMI A, IZUMI M et al.: Detection of the soluble form of Fas ligand (sFasL) and sFas in the saliva from patients with Sjögren's syndrome. Clin Exp Rheumatol. 2005; 23: 915.
8. OHLSSON M, SKARSTEIN K, BOLSTAD AI, JOHANNESSEN AC, JONSSON R: Fas-induced apoptosis is a rare event in Sjögren's syndrome. Lab Invest 2001; 81: 95-105.
9. OHLSSON M, SZODORAY P, LORO LL, JOHANNESSEN AC, JONSSON R: CD40, CD154, Bax and Bcl-2 expression in Sjögren's syndrome salivary glands: A putative anti-apoptotic role during its effector phases. Scand J Immunol 2002; 56: 561-71.
10. NAKAMURA H, KAWAKAMI A, TOMINAGA M et al.: Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjögren's syndrome. Lab Invest. 1999; 79: 261-9.
11. NAKAMURA H, KAWAKAMI A, YAMASAKI S et al.: Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sjögren's syndrome. Lab Invest 2000; 80: 1421-7.
12. FRANKE TF, HORNIK CP, SEGEV L, SHOSTAK GA, SUGIMOTO C: PI3K/Akt and apoptosis: Size matters. Oncogene 2003; 22: 8983-98.
13. AHN JY, RONG R, LIU X, YE K: PIKE/nuclear PI 3-kinase signaling mediates the antiapoptotic actions of NGF in the nucleus. EMBO J. 2004; 23: 3995-4006.
14. ROMASHKOVA JA, MAKAROV SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signaling. Nature 1999; 401: 86-90.
15. VIATOUR P, MERVILLE MP, BOURS V, CHARIOT A: Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem Sci 2005; 30: 43-52.
16. NAKAMURA H, KAWAKAMI A, IDA H, KOJI T, EGUCHI K: EGF activates PI3K-Akt and NF-KB via distinct pathways in salivary epithelial cells in Sjögren's syndrome. Rheumatol Int 2007; 28: 127-36.
17. VITALI C, BOMBARDIERI S, JONSSON R et al.: Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
18. NAKAMURA H, KOJI T, TOMINAGA M et al.: Apoptosis in labial salivary glands from Sjögren's syndrome (SS) patients: Comparison with human T lymphotropic virus-I (HTLV-I)-seronegative and -seropositive SS patients. Clin Exp Immunol 1998; 114: 106-12.
19. MATSUMURA R, UMEMIYA K, GOTO T et al.: Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 2000; 18: 311-8.
20. MORIMOTO Y, MORIMOTO H, OKAMURA H et al.: Upregulation of the expression of Fas antigen and Fas ligand in a human submandibular gland ductal cell line by okadaic acid. Arch Oral Biol 2000; 45: 657-66.
21. CHOSA N, KYAKUMOTO S, KITO N, KAMO M, SATO N: Mechanism of Fas-mediated cell death and its enhancement by TNF-alpha in human salivary gland adenocarcinoma. cell line HSG. Eur J Oral Sci 2004; 112: 338-46.
22. PING L, OGAWA N, SUGAI S: Novel role of CD40 in Fas-dependent apoptosis of cultured salivary epithelial cells from patients with Sjögren's syndrome. Arthritis Rheum 2005; 52: 573-81.
23. KRYSTAL GW, SULANKE G, LITZ J: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002; 1: 913-22.
24. LEE YC, TANG YC, CHEN YH, WONG CM, TSOU AP: Selenite-induced survival of HuH7 hepatoma cells involves activation of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt pathway and Rac1. J Biol Chem. 2003; 278: 39615-24.
25. TAKEDA A, OSAKI M, ADACHI K, HONJO S, ITO H: Role of the phosphatidylinositol 3′- kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines. Pancreas 2004; 28: 353-8.
26. KAKAZU A, CHANDRASEKHER G, BAZAN HE: HGF protects corneal epithelial cells from apoptosis by the PI-3K/Akt-I/Bad- but not the ERK1/2-mediated signaling pathway. Invest Ophthalmol Vis Sci 2004; 45: 3485-92.
27. XIAO GH, JEFFERS M, BELLACOSA A, MITSUUCHI Y, VAN DE WOUDE GF, TESTA JR: Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001; 98: 247-52.
28. NAKAMURA H, KAWAKAMI A, YAMASAKI S, KAWABE Y, NAKAMURA T, EGUCHI K: Expression of mitogen activated protein kinases in labial salivary glands of patients with Sjögren's syndrome. Ann Rheum Dis 1999; 58: 382-5.
29. SOEJIMA K, NAKAMURA H, TAMAI M, KAWAKAMI A, EGUCHI K: Activation of MKK4 (SEK1), JNK, and c-Jun in labial salivary infiltrating T cells in patients with Sjögren's syndrome. Rheumatol Int 2007; 27: 29-33.
30. GIBSON S, TU S, OYER R, ANDERSON SM, JOHNSON GL: Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 1999; 274: 17612-8.
31. BISWAS DK, CRUZ AP, GANSBERGER E, PARDEE AB: Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000; 97: 8542-7.